REGEN BIOPHARMA, INC. (RGBP) Total liabilities 2017–2025
REGEN BIOPHARMA, INC. (RGBP) total liabilities at each fiscal year-end, per SEC filings.
$6.6MFY2025 · since FY2017: $6.2M → $6.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $6.6M | +21.9% |
| FY2024 | $5.4M | -1.5% |
| FY2023 | $5.5M | -36.5% |
| FY2022 | $8.6M | -41.5% |
| FY2021 | $14.7M | +97.1% |
| FY2020 | $7.5M | -32.2% |
| FY2019 | $11.0M | +18.0% |
| FY2018 | $9.3M | +50.6% |
| FY2017 | $6.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RGBP financial trends
RGBP RevenueRGBP Net incomeRGBP Net marginRGBP Gross profitRGBP Gross marginRGBP Operating incomeRGBP Operating marginRGBP Operating cash flowRGBP Free cash flowRGBP Capital expendituresRGBP Return on equityRGBP Stock buybacksRGBP Dividends paidRGBP Total assetsRGBP Shareholders’ equityRGBP overview →